Your browser is no longer supported. Please, upgrade your browser.
Settings
TNXP Tonix Pharmaceuticals Holding Corp. daily Stock Chart
TNXP [NASD]
Tonix Pharmaceuticals Holding Corp.
Index- P/E- EPS (ttm)-14.00 Insider Own1.77% Shs Outstand15.50M Perf Week-8.30%
Market Cap6.51M Forward P/E- EPS next Y-2.69 Insider Trans12.29% Shs Float15.22M Perf Month-24.46%
Income-28.40M PEG- EPS next Q-0.96 Inst Own9.30% Short Float5.68% Perf Quarter-79.31%
Sales- P/S- EPS this Y15.40% Inst Trans261.73% Short Ratio1.25 Perf Half Y-77.89%
Book/sh2.08 P/B0.20 EPS next Y33.60% ROA-146.80% Target Price4.83 Perf Year-96.47%
Cash/sh0.79 P/C0.53 EPS next 5Y- ROE-167.10% 52W Range0.43 - 12.00 Perf YTD-80.91%
Dividend- P/FCF- EPS past 5Y39.70% ROI- 52W High-96.50% Beta1.39
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low-2.35% ATR0.04
Employees12 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)25.56 Volatility12.45% 9.70%
OptionableNo Debt/Eq0.00 EPS Q/Q86.90% Profit Margin- Rel Volume0.49 Prev Close0.45
ShortableYes LT Debt/Eq0.00 EarningsAug 12 Payout- Avg Volume690.48K Price0.42
Recom2.00 SMA20-12.68% SMA50-52.52% SMA200-80.69% Volume338,145 Change-6.67%
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
Aug-21-19 07:00AM  Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonixs Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection GlobeNewswire
Aug-20-19 07:00AM  Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD GlobeNewswire +8.89%
Aug-12-19 08:00AM  Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights GlobeNewswire
Aug-02-19 04:05PM  Tonix Pharmaceuticals Announces Director Stepping Down GlobeNewswire
Jul-25-19 07:00AM  Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL GlobeNewswire
Jul-18-19 04:05PM  Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock GlobeNewswire
Jul-16-19 08:30AM  Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -40.66%
Jun-13-19 07:00AM  Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL GlobeNewswire
Jun-10-19 01:05PM  TNXP: Enrollment Continues for Phase 3 Trial of TNX-102 SL in PTSD Zacks Small Cap Research
May-30-19 08:00AM  Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology GlobeNewswire
May-28-19 04:15PM  Tonix Pharmaceuticals to Present at BIO 2019 International Convention GlobeNewswire -8.87%
07:43AM  How Does Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Affect Your Portfolio Volatility? Simply Wall St.
May-23-19 07:00AM  Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication GlobeNewswire -6.40%
May-21-19 04:15PM  Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology GlobeNewswire +9.62%
May-17-19 04:05PM  Tonix Pharmaceuticals Announces Director Stepping Down GlobeNewswire
May-13-19 08:00AM  Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights GlobeNewswire -9.50%
May-08-19 07:00AM  Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA GlobeNewswire
Apr-23-19 01:51PM  Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) GlobeNewswire
Apr-22-19 07:00AM  Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder GlobeNewswire
Apr-19-19 06:49AM  Tonix Pharmaceuticals R&D pact with U.S. Army to be terminated 'without cause' MarketWatch
Apr-10-19 01:45PM  TNXP: Phase 3 Trial of TNX-102 SL in PTSD Underway Zacks Small Cap Research
Apr-04-19 02:35PM  Four Healthcare Stocks Heating Up on Thursday ACCESSWIRE +20.60%
10:21AM  What's Driving The Rally In Nanocap Biotech Tonix Pharma? Benzinga
07:30AM  Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia GlobeNewswire
Mar-25-19 08:00AM  Tonix Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Mar-18-19 08:00AM  Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights GlobeNewswire
Mar-12-19 07:30AM  Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences GlobeNewswire -11.87%
Mar-11-19 09:35AM  Four Healthcare Stocks Making Moves on Monday ACCESSWIRE +20.36%
07:00AM  Tonix Pharmaceuticals Enrolls First Participant in the RECOVERY Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder GlobeNewswire
Mar-08-19 01:35PM  Four Healthcare Stocks Surpassing Investor Expectations ACCESSWIRE +30.84%
Mar-07-19 04:15PM  Tonix Pharmaceuticals Announces New European Use Patent for TNX-601 GlobeNewswire +19.55%
Mar-01-19 05:41PM  Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder GlobeNewswire +6.95%
04:00PM  Tonix Pharmaceuticals Announces Share Repurchase Program GlobeNewswire
Feb-19-19 04:30PM  Tonix Pharmaceuticals Announces New Board Member, James Treco GlobeNewswire
Feb-06-19 12:17PM  How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares? Simply Wall St.
Feb-04-19 08:00AM  Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference GlobeNewswire
Jan-03-19 09:45AM  TNXP: Additional Details Revealed for Phase 3 Trial of TNX-102 SL in PTSD Starting in 1Q19 Zacks Small Cap Research -7.59%
Jan-02-19 07:00AM  Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion GlobeNewswire
Dec-18-18 07:00AM  Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement GlobeNewswire
Dec-11-18 04:00PM  Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering GlobeNewswire
Dec-07-18 01:37PM  Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today InvestorPlace -6.67%
10:35AM  Tonix Pharmaceuticals Prices $15,000,000 Public Offering GlobeNewswire
Dec-03-18 07:00AM  Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target ACCESSWIRE -22.16%
Nov-29-18 07:00AM  Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes GlobeNewswire +83.42%
Nov-27-18 07:00AM  Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split GlobeNewswire -8.49%
Nov-21-18 07:35AM  Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-19-18 09:45AM  TNXP: Ready to Initiate Phase 3 Trial of TNX-102 SL in PTSD in 1Q19 Zacks Small Cap Research
Nov-09-18 07:53AM  Tonix: 3Q Earnings Snapshot Associated Press -10.29%
07:30AM  Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Nov-07-18 07:00AM  Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya® GlobeNewswire
Nov-06-18 07:00AM  Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 HONOR Study in Poster Presentation at CNS Summit 2018 GlobeNewswire
Nov-01-18 08:00AM  Todays Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals ACCESSWIRE -5.56%
07:00AM  Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference GlobeNewswire
Oct-31-18 10:05AM  Healthcare Market Growth Could Fuel These Stocks ACCESSWIRE +12.50%
07:00AM  Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting GlobeNewswire
Oct-29-18 07:00AM  Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018 GlobeNewswire
Oct-23-18 07:00AM  Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference GlobeNewswire
Oct-04-18 08:00AM  Todays Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies ACCESSWIRE
Sep-26-18 01:30PM  Tonix Pharmaceuticals to Present at the MicroCap Conference GlobeNewswire
Sep-20-18 07:00AM  Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference GlobeNewswire
Sep-07-18 07:00AM  Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D. GlobeNewswire
Aug-30-18 07:00AM  Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences GlobeNewswire
Aug-27-18 03:45PM  TNXP: Retrospective Analyses from HONOR and AtEase Trials Presented Zacks Small Cap Research
Aug-22-18 04:01PM  Tonix Pharmaceuticals Announces Director Stepping Down GlobeNewswire -8.46%
Aug-21-18 09:20AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium GlobeNewswire
Aug-15-18 11:46AM  Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium GlobeNewswire +13.73%
Aug-13-18 07:07AM  Tonix: 2Q Earnings Snapshot Associated Press
07:00AM  Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Aug-09-18 12:00PM  TNXP: HONOR Trial Stopped Early Following Interim Analysis... Zacks Small Cap Research
Jul-27-18 08:55AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga -65.78%
08:00AM  Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD GlobeNewswire
Jul-17-18 08:10AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Tonix Pharmaceuticals ACCESSWIRE
Jul-16-18 01:51PM  Tonix Shares Surge On Fast Struck Status For Alzheimer's-Related Agitation Candidate Benzinga +5.82%
09:26AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimers Disease GlobeNewswire
Jun-20-18 09:02AM  Bullish Insiders Bought More Of These Stocks In June Simply Wall St.
May-31-18 04:30PM  Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology GlobeNewswire +5.86%
May-30-18 08:00AM  Tonix Pharmaceuticals to Present at the 2018 BIO International Convention GlobeNewswire
May-24-18 07:00AM  Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL GlobeNewswire
May-23-18 04:05PM  Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology GlobeNewswire
May-14-18 07:08AM  Tonix: 1Q Earnings Snapshot Associated Press
07:00AM  Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update GlobeNewswire
May-07-18 07:00AM  Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention GlobeNewswire
May-01-18 08:24AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimers Disease GlobeNewswire
Apr-05-18 07:10AM  Blog Exposure - Tonix Pharma Announces 50% Enrolment in Tonmya® Study for PTSD ACCESSWIRE
Apr-04-18 07:00AM  Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York GlobeNewswire
Apr-03-18 07:00AM  Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD GlobeNewswire
Mar-26-18 04:05PM  Eyenovia Appoints Three Industry Veterans to Board of Directors GlobeNewswire
Mar-21-18 04:05PM  Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL GlobeNewswire
Mar-19-18 04:45PM  TNXP: Phase 3 Trial in PTSD Nearing 50% Enrollment; Interim Analysis in 3Q18 Zacks Small Cap Research -5.37%
Mar-13-18 07:00AM  Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium GlobeNewswire
Mar-12-18 07:23AM  Tonix reports 4Q loss Associated Press
07:00AM  Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update GlobeNewswire
Mar-06-18 07:00AM  Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-15-18 07:00AM  Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors GlobeNewswire
Feb-07-18 04:30PM  Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City GlobeNewswire
Jan-24-18 04:30PM  Tonix Pharmaceuticals to Present at Noble Capital Markets Fourteenth Annual Investor Conference in Fort Lauderdale GlobeNewswire -7.51%
Jan-23-18 09:30AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +5.45%
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEDERMAN SETHChief Executive OfficerMar 29Buy2.495,00012,44032,670Apr 01 08:22 AM
LEDERMAN SETHChief Executive OfficerMar 26Buy2.3825,00059,37527,670Mar 28 05:13 PM